Pharmacogenetics of 6-Mercaptopurine in a Black Zimbabwean Cohort Treated for Acute Lymphoblastic Leukaemia
Pharmacogenomics · 2023
DOI: 10.2217/pgs-2023-0026 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacogenomics, 2023. Verfasst von Pageneck Chikondowa und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genomic Medicine, African Institute of Biomedical Science & Technology (AiBST), Harare, Zimbabwe. Hauptthemen laut MEDLINE: Mercaptopurine, Precursor Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Bill & Melinda Gates Foundation, NIH HHS.
Abstract (Originalsprache)
Background
6-mercaptopurine usage is associated with myelotoxicity and increased risk in patients carrying metabolism-related genetic variations. This study aimed to determine the frequency of candidate gene polymorphisms and their association with 6-mercaptopurine intolerance.
Methods
A total of 41 patients on acute lymphoblastic leukaemia treatment were genotyped for TPMT and NUDT15 (rs116855232) alleles, and their association with dose intensity was analyzed.
Results
The defective TPMT*3C allele frequency was 9.8%. The median maintenance dose intensity for TPMT*1/*3C participants was considerably lower (47%) when compared with the TPMT*1/*1 wild-type (77%), although not statistically significant.
Conclusion
This is the first pharmacogenetics study carried out in a black Zimbabwean leukemia patient cohort. The high defective TPMT*3C (9.8%) allele frequency points to the potential utility of pharmacogenetics testing for safe usage of 6-mercaptopurine in this population. Acute lymphoblastic leukemia (ALL) is the most common malignancy affecting children in Zimbabwe and 6-mercaptopurine is frequently used as part of its treatment. However, 6-mercaptopurine is associated with side-effects such as severe neutropenia (a condition where you have a low number of white blood cells called neutrophils in your blood), with increased risk observed in patients carrying variants in genes involved in the metabolism of 6-mercaptopurine. Therefore, this study aimed to determine the frequency of polymorphisms in specific genes as well as their association with drug intolerance. A total of 41 patients on ALL treatment were studied. Review of treatment records was done to determine the cumulative 6-mercaptopurine dose and calculate dose intensity. Genotyping (to determine the versions of a gene a patient carries) for TPMT and NUDT15 (rs116855232) was performed and results correlated with drug dose intensity. The most frequent genotype was TPMT*1/*1, occurring in 80% of the participants. The remaining 20% were carriers with two different copies of TPMT (*1/*3C). The defective TPMT*3C variation occurred at 9.8% and none had TPMT*2, *3A, *3B or NUDT15 rs116855232 variants. Comparison analysis with dose intensity was done for 23 participants (56%) who had maintenance records available. The median dose intensity of 47% for TPMT*1/*3C participants was considerably low when compared to that of a normal TPMT*1/*1 patient, which was 77%. However, no statistically significant difference was observed between TPMT genotype and dose intensity. This is the first study in a group of leukemic Zimbabweans to investigate the frequency of TPMT and NUDT15 variants. With a high variation frequency of 9.8% for the defective TPMT*3C, pharmacogenetics testing for TPMT before treatment with 6-MP is recommended in the Zimbabwean population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Genomic Medicine, African Institute of Biomedical Science & Technology (AiBST), Harare, Zimbabwe.
- Department of Biotechnology, School of Health Science & Technology, Chinhoyi University of Technology, Chinhoyi, Zimbabwe.
- Department of Pharmacy, School of Health Sciences, University of Zambia, Lusaka, 10101, Zambia.
- Department of Paediatrics, Faculty of Medicine & Health Sciences, University of Zimbabwe, Harare, Zimbabwe.
ORCID-Profile: Pageneck Chikondowa, Zedias Chikwambi, Patience Kuona, Collen Masimirembwa
Förderung
- NCI NIH HHS
- Bill & Melinda Gates Foundation
- NIH HHS
- Bill and Melinda Gates Foundation (BMGF) grant
- European & Developing Countries Clinical Trials Partnership grant
- National Institute of Health (NIH) Grant
Zitieren
APA
Chikondowa, P., Munkombwe, D., Chikwambi, Z., Kuona, P., & Masimirembwa, C. (2023). Pharmacogenetics of 6-Mercaptopurine in a Black Zimbabwean Cohort Treated for Acute Lymphoblastic Leukaemia. Pharmacogenomics. https://doi.org/10.2217/pgs-2023-0026
Vancouver
Chikondowa P, Munkombwe D, Chikwambi Z, Kuona P, Masimirembwa C. Pharmacogenetics of 6-Mercaptopurine in a Black Zimbabwean Cohort Treated for Acute Lymphoblastic Leukaemia. Pharmacogenomics. 2023. doi:10.2217/pgs-2023-0026
BibTeX
@article{Chikondowa2023,
author = {Chikondowa, Pageneck and Munkombwe, Derick and Chikwambi, Zedias and Kuona, Patience and Masimirembwa, Collen},
title = {Pharmacogenetics of 6-Mercaptopurine in a Black Zimbabwean Cohort Treated for Acute Lymphoblastic Leukaemia},
journal = {Pharmacogenomics},
year = {2023},
doi = {10.2217/pgs-2023-0026}
}
EUVIMED